from BIOMERIEUX (EPA:BIM)
bioMérieux presents its new 5-year strategic plan and its targets for profitable growth
bioMérieux presents its new 5-year strategic plan and its targets for profitable growth
Marcy l’Étoile, France, April 9, 2024 – bioMérieux, a world leader in the field in vitro diagnostics, is hosting today a Capital Markets Day in Paris. On this occasion, Pierre Boulud, Chief Executive Officer, together with members of the Executive Committee will present bioMérieux’s strategic plan, GO•28, the new chapter for the Company’s growth and development.
Pierre Boulud, Chief Executive Officer, said: “bioMérieux has delivered a remarkable performance over the last few years and is emerging from the COVID-19 period stronger and more diversified. With the GO•28 plan, we are presenting today an ambitious medium term strategy for profitable and sustainable growth to better serve our purpose to help make the world a healthier place.”
bioMérieux’s strategy is composed of four dimensions:
• to pursue its strong organic growth, building on its comprehensive portfolio of solutions further supported by continuous innovation,
• to simplify its operating model to increase its efficiency and profitability,
• to act responsibly for the benefit of its team members, patients, consumers and the planet
• to grow stronger and more agile as an organization by empowering and engaging all team members.
Assuming no significant change to the current market environment, with the GO•28 plan, bioMérieux aims to reach the following targets:
• Organic revenue growth1 of +7%, CAGR2 2024 / 2028
• Contributive Operating Income before non recurring items[1] improving to 20% of sales in 2028 at constant exchange rates and scope (from 16.5% in 2023), with an annual organic increase of at least 10% per year until 2028
• Annual Capex: around 8 to 10% of annual sales for the period 2025 / 2028
• Dividend pay-out ratio policy of around 25% of the annual Group net income
• Renewed commitment to deliver on the Corporate Social Responsibility strategy and notably an ambitious -50% decrease in GHG absolute emissions in 2030 vs. 2019 for scope 1&2
The webcast of the Capital Markets Day will start at 9:30am Paris time (GMT+1) and will be accessible using the following link: https://event.webcasts.com/starthere.jsp?ei=1665435&tp_key=77f5435e46
The replay and the related presentation will be available at www.biomerieux.com after the event.
|
1 Organic growth corresponds to year-on-year sales growth at constant scope and currencies and excludes the impact of hyperinflation, recognized in accordance with IAS 29. 2 Compound Annual Growth Rate |
ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics for 60 years, bioMérieux is present in 45 countries and serves more than 160 countries with the support of a large network of distributors. In 2023, revenues reached €3.7 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agrifood, pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market. Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP
Corporate website: www.biomerieux.com
CONTACTS
|
Investor Relations |
|
|
bioMérieux |
|
|
Aymeric Fichet |
|
|
Tel.: +33 (0)4 78 87 20 00 |
|
|
investor.relations@biomerieux.com |
|
|
|
|
|
Media Relations |
|
|
bioMérieux |
Image Sept |
|
Romain Duchez |
Laurence Heilbronn |
|
Tel.: +33 (0)4 78 87 20 00 |
Tel.: +33 (0)1 53 70 74 64 |
|
media@biomerieux.com |
lheilbronn@image7.fr |
[1] Contributive operating income before non-recurring items corresponds to operating income excluding amortization and impairment of intangible assets related to acquisitions and acquisition-related costs